14.50
+2.84%
Close of 9 Nov 2026, in EUR
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Formycon
Its shares trade on XETRA under the ticker FYB.DE. It has been listed since 20 December 2010. In the fiscal year to 31 December 2025, it reported revenue of €44.5m and a net loss of €64.7m. At that date it held total assets of €739.5m and shareholders' equity of €399.1m.
Formycon AG engages in the manufacture of biosimilar drugs and formulations. The company is headquartered in Martinsried, Bayern. The company went IPO on 2010-12-20. Its business activities are focused on the development and marketing of biopharmaceuticals that are similar to existing drugs, for which the patent protection is expiring. The firm focuses on treatments in the area of ophthalmology, immunology and other chronic diseases, covering all steps of biosimilar development process, from early-stage analysis of the originator drug to the preclinical and clinical testing phases, as well as the preparation of dossiers for marketing approval. Its biosimilar product pipeline consists of four candidates in pre-clinical and clinical testing phases, including FYB201, a biosimilar candidate for Lucentis; FYB202, a biosimilar candidate for Stelara; FYB203, a biosimilar candidate for Eylea, and FYB205.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 20 Dec 2010
- Employees
- 119
- Website
- formycon.com ↗
Leadership
Pay as last reported
- Mr. Wolfgang EsslerChairman of the Supervisory Board, since 2023€67,800
- Dr. Stefan GlombitzaChief Executive Officer, Member of the Executive Board€612,300
- Mr. Colin BondIndependent Deputy Chairman of Supervisory Board, since 2024€22,500
- Mr. Enno SpillnerChief Financial Officer, Member of the Executive Board€560,900
- Dr. Andreas SeidlChief Scientific Officer, Member of the Executive Board€339,500
- Ms. Nicola MikulcikMember of the Executive Board, Chief Business Officer€393,800
- Dr. Bodo ColdeweyIndependent Member of the Supervisory Board€29,300
- Mr. Nicholas HaggarIndependent Member of the Supervisory Board, since 2024€35,800
- Mr. Klaus RoehrigMember of the Supervisory Board€39,000
- Ms. Sabrina MuellerDirector Investor Relations and Corporate Communications, since 2025
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Formycon AG has a strong portfolio of biosimilar products, positioning itself as a key player in the pharmaceutical industry.
- The company's partnerships with major pharmaceutical companies provide it with access to resources, expertise, and distribution channels.
- Formycon AG has a robust research and development pipeline, constantly working on innovative solutions and enhancing its product offerings.
Weaknesses
- The company heavily relies on its partnerships, making it susceptible to changes in business relationships and potential dependency.
- Formycon AG may face challenges in obtaining regulatory approvals for its biosimilar products, which can lead to delays and increased costs.
- The company's limited marketing and promotional activities may hinder its ability to fully exploit market opportunities.
Opportunities
- The increasing demand for affordable healthcare and cost-effective treatment options creates significant opportunities for Formycon AG's biosimilars.
- Expansion into new markets and regions presents the company with the chance to diversify its revenue streams and strengthen its global presence.
- Strategic collaborations with emerging biotechnology companies can facilitate knowledge exchange and open doors to new research and development opportunities.
Threats
- Intense competition from rival companies operating in the biosimilars market poses a threat to Formycon AG's market share and potential profitability.
- Changes in healthcare regulations and pricing policies can impact the reimbursement rates and financial viability of the company's products.
- Emerging technologies or alternative treatment options could disrupt the demand for Formycon AG's biosimilars.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.